Article
Oncology
Michela Buglione, Daniela Alterio, Marta Maddalo, Diana Greco, Marianna Alessandra Gerardi, Davide Tomasini, Ludovica Pegurri, Matteo Augugliaro, Giulia Marvaso, Irene Turturici, Andrea Guerini, Mohssen Ansarin, Luigi Spiazzi, Loredana Costa, Maria Cossu Rocca, Stefano Maria Magrini, Barbara Alicja Jereczek-Fossa
Summary: This study compared the effects of different dosing schedules of CDDP on patients with H&N squamous cell cancer. The results showed that while patients in the 3w-CDDP group had certain advantages, overall, the two schedules had similar impacts on acute toxicity and survival rates.
RADIATION ONCOLOGY
(2021)
Article
Oncology
Tejpal Gupta, Sadhana Kannan, Sarbani Ghosh-Laskar, Jai Prakash Agarwal
Summary: Cisplatin-based concurrent chemoradiotherapy is the standard treatment for head and neck squamous cell carcinoma. The optimal dose-schedule of cisplatin remains debated, but emerging evidence suggests that once-weekly cisplatin is as effective as three-weekly cisplatin for disease-related outcomes.
Article
Oncology
An-An Xu, Jing-Jing Miao, Lin Wang, An-Chuan Li, Fei Han, Xun-Fan Shao, Zhi-Wen Mo, Shao-Min Huang, Ya-Wei Yuan, Xiao-Wu Deng, Chong Zhao
Summary: This study analyzed the clinical outcomes of concurrent chemoradiotherapy (CCRT) alone for loco-regionally advanced nasopharyngeal carcinoma (LANPC) based on 10-year results, aiming to provide evidence for individualized treatment strategy and designing appropriate clinical trial for different risk LANPC patients.
RADIATION ONCOLOGY
(2023)
Article
Otorhinolaryngology
Mei-Kim Ang, Jose Enrique Montoya, Ekkasit Tharavichitkul, Cindy Lim, Terence Tan, Lan Ying Wang, Joseph Wee, Yoke-Lim Soong, Kam-Weng Fong, Quan Sing Ng, Daniel Shao-Weng Tan, Chee-Keong Toh, Eng-Huat Tan, Wan-Teck Lim
Summary: In this study, the combination of nimotuzumab with cisplatin and radiotherapy was found to be safe and effective in treating locally advanced head and neck squamous cell carcinoma, with high response rates observed in patients.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
(2021)
Article
Otorhinolaryngology
Stefano Cavalieri, Ester Orlandi, Eliana Ivaldi, Cristiana Bergamini, Salvatore Alfieri, Nicola Alessandro Iacovelli, Rossana Ingargiola, Carlo Resteghini, Francesca Platini, Giulia Apollonio, Teresa Beninato, Fabiola Incandela, Walter Fontanella, Lorenzo Bresciani, Lorenzo Giannini, Cesare Piazza, Lisa Licitra, Laura Deborah Locati
Summary: In this study, the management and outcomes of loco-regionally advanced laryngeal cancer in elderly patients were retrospectively analyzed. The results showed that age and TNM staging play independent prognostic roles in elderly patients with laryngeal cancer, with a significant portion of them requiring more organ-preservation treatment due to comorbidities.
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY
(2021)
Article
Oncology
Shogo Shinohara, Shinji Takebayashi, Kiyomi Hamaguchi, Tetsuhiko Michida, Yota Tobe, Tadashi Ikenaga, Mami Yasumoto, Ayami Hamamoto, Toshiyuki Imagumbai, Takamasa Mitsuyoshi, Ryo Ashida, Takahiro Iwai, Shun Okabayashi
Summary: Concurrent chemoradiotherapy with low-dose weekly cisplatin (LDC) was found to be well-tolerated and effective in treating patients with head and neck squamous cell carcinoma (HNSCC). Despite some toxicities, patients were able to complete radiation therapy with a high overall survival rate. Total cisplatin dose and age distribution did not significantly impact survival outcomes.
CLINICAL MEDICINE INSIGHTS-ONCOLOGY
(2021)
Article
Oncology
Y. Tao, J. Biau, X. S. Sun, C. Sire, L. Martin, M. Alfonsi, J. B. Prevost, A. Modesto, C. Lafond, J. M. Tourani, J. Miroir, M. C. Kaminsky, A. Coutte, X. Liem, E. Chautard, E. Vauleon, F. Drouet, A. Ruffer, J. F. Ramee, G. Waksi, A. Pechery, M. Wanneveich, J. Guigay, A. Auperin, J. Bourhis
Summary: This study aimed to evaluate the potential synergistic effect of pembrolizumab with radiotherapy compared with a standard-of-care cetuximab-radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). The results showed that pembrolizumab concomitant with radiotherapy did not improve tumor control and survival compared with cetuximab-radiotherapy, but it appeared to be less toxic in unfit patients with LA-SCCHN.
ANNALS OF ONCOLOGY
(2023)
Review
Oncology
Francesca De Felice, Liliana Belgioia, Daniela Alterio, Pierluigi Bonomo, Marta Maddalo, Fabiola Paiar, Nerina Denaro, Renzo Corvo, Anna Merlotti, Paolo Bossi, Giovanni L. Pappagallo, Rolando M. D'Angelillo, Stefano M. Magrini, Stefano Arcangeli
Summary: Comparing weekly cisplatin with three-weekly cisplatin chemoradiotherapy for locally advanced head and neck cancer, the study found that there were no significant differences in clinical outcomes and toxicity, but the compliance to treatment was higher in the three-weekly regimen.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Francesca De Felice, Daniela Musio, Vincenzo Tombolini
Summary: Weekly hypofractionated radiation therapy has shown effective cure and good tolerance for inoperable cSCC of the head and neck region. Further clinical trials are needed to confirm the efficacy of this treatment approach.
Article
Oncology
Li-Ting Liu, Huai Liu, Ying Huang, Jin-Hao Yang, Si-Yi Xie, Yuan-Yuan Li, Shan-Shan Guo, Bin Qi, Xiao-Yun Li, Dong-Ping Chen, Feng Jin, Xue-Song Sun, Zhen-Chong Yang, Sai-Lan Liu, Dong-Hua Luo, Ji-Bin Li, Qing Liu, Pan Wang, Ling Guo, Hao-Yuan Mo, Fang Qiu, Qi Yang, Yu-Jing Liang, Guo-Dong Jia, Dong-Xiang Wen, Jin-Jie Yan, Chong Zhao, Qiu-Yan Chen, Rui Sun, Lin-Quan Tang, Hai-Qiang Mai
Summary: The efficacy and safety of concurrent adjuvant cisplatin-gemcitabine were compared with cisplatin-fluorouracil in N2-3 nasopharyngeal carcinoma. The 3-year progression-free survival was significantly higher in the cisplatin-gemcitabine group (83.9%) compared to the cisplatin-fluorouracil group (71.5%). The adverse events were similar between the two groups. Therefore, cisplatin-gemcitabine could be considered as an adjuvant therapy option for patients with N2-3 nasopharyngeal carcinoma.
Article
Oncology
Naomi Kiyota, Makoto Tahara, Junki Mizusawa, Takeshi Kodaira, Hirofumi Fujii, Tomoko Yamazaki, Hiroki Mitani, Shigemichi Iwae, Yasushi Fujimoto, Yusuke Onozawa, Nobuhiro Hanai, Takenori Ogawa, Hiroki Hara, Nobuya Monden, Eiji Shimura, Shujiro Minami, Takashi Fujii, Kaoru Tanaka, Akihiro Homma, Seiichi Yoshimoto, Nobuhiko Oridate, Koichi Omori, Tsutomu Ueda, Kenji Okami, Ichiro Ota, Kiyoto Shiga, Masashi Sugasawa, Takahiro Asakage, Yuki Saito, Shigeyuki Murono, Yasumasa Nishimura, Kenichi Nakamura, Ryuichi Hayashi
Summary: The study demonstrates that chemoradiotherapy with weekly cisplatin is noninferior to 3-weekly cisplatin in terms of overall survival for patients with postoperative high-risk locally advanced squamous cell carcinoma of the head and neck. Weekly cisplatin also leads to fewer adverse reactions compared to the 3-weekly regimen.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Yushi Ueki, Shusuke Ohshima, Yusuke Yokoyama, Takeshi Takahashi, Ryusuke Shodo, Keisuke Yamazaki, Kohei Ohtaki, Kohei Saijo, Ryoko Tanaka, Takafumi Togashi, Yuichiro Sato, Satoshi Takano, Jo Omata, Nao Takahashi, Ryuichi Okabe, Arata Horii
Summary: This study evaluated the feasibility, efficacy, and safety of concurrent chemoradiotherapy (CCRT) with weekly low-dose carboplatin for cisplatin-ineligible advanced head and neck squamous cell carcinoma (HNSCC) patients. The results showed that this treatment option had high completion rate and overall response rate, with acceptable toxicity.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Maria Gebre-Medhin, Eva Brun, Per Engstrom, Hedda Haugen Cange, Lalle Hammarstedt-Nordenvall, Johan Reizenstein, Jan Nyman, Edvard Abel, Signe Friesland, Helena Sjodin, Henrik Carlsson, Karin Soderkvist, Marcus Thomasson, Bjorn Zackrisson, Per Nilsson
Summary: The study demonstrates that for patients with locoregionally advanced HNSCC, cisplatin is superior to cetuximab in terms of locoregional control when used in combination with radiotherapy.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Ming Yin Lin, Linda Mileshkin, Orla McNally, Srinivas Kondalsamy-Chennakesavan, Kailash Narayan
Summary: This study aimed to analyze the survival of cervical cancer patients and identify isoprognostic groups based on primary tumor volume and nodal status. The results showed heterogeneous survival rates according to FIGO 2018 staging, while progressively worsening prognosis could be demonstrated in the observed isoprognostic clusters. Therefore, further research is needed to determine the most appropriate treatment modality and improve patient selection for clinical trials.
GYNECOLOGIC ONCOLOGY
(2023)
Article
Oncology
Hui Jiang, Qiaoqiao Li, Baoqing Chen, Mian Xi, Kanjiebubi Makelike, Shiliang Liu, Yonghong Hu, Yujia Zhu
Summary: This study aimed to evaluate the safety, dose-limiting toxicity, maximum tolerated dose, and preliminary effect of nanoparticle albumin-bound paclitaxel in combination with concurrent chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma. The results showed that this treatment regimen was effective and well-tolerated for patients with locally advanced esophageal squamous cell carcinoma.